Buy & Sell Utilities Select Sector SPDR Fund (XLU) – Utilities Select Sector SPDR Fund Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Sector
- -8.8%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 69 daysTypical Hold Time
Over the past 52 weeks, Utilities Select Sector SPDR Fund has traded between a low of $40.17 and a high of $47.73, highlighting its annual price range. Over the past three months, Utilities Select Sector SPDR Fund has recorded a drawdown of -8.8%, reflecting recent price volatility. On average, investors hold Utilities Select Sector SPDR Fund for approximately 69 days, indicating typical investor behavior on the platform.
About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Most Recent News
Cyabra inks $500K+ deal to fight online hate with AI-powered disinformation detection for global research institute
Cyabra, an AI-driven disinformation intelligence company, has secured a contract worth over $500,000 to provide its technology to a leading international research institute focused on tracking global hate speech. The platform will help identify coord...

Ormat launches Ormega100, the largest binary geothermal unit, to boost Enhanced Geothermal System deployment.
Ormat Technologies introduced the Ormega100, the industry's largest binary power generation unit delivering 100 MW output, designed to accelerate commercialization and scaling of Enhanced Geothermal Systems (EGS). With 60 years of expertise and exten...

ADARx to present Phase 1/2 data on Onvuzosiran for hereditary angioedema at 2026 EAACI Congress
ADARx Pharmaceuticals announced it will present Phase 1/2 clinical data for Onvuzosiran, an RNA therapy for hereditary angioedema (HAE), at the 2026 EAACI Congress in Istanbul. Onvuzosiran targets plasma prekallikrein to prevent swelling attacks by r...
